Bladder flat intraepithelial lesion

Summary

Bladder flat intraepithelial lesion (MONDO:0006111) is a disease. A subtype of urinary bladder neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bladder flat intraepithelial lesion
Mondo ID	MONDO:0006111
EFO	EFO:1000126
DOID	DOID:5429
NCIT	C37266
UMLS	C1332559
MedGen	231947
Is cancer (heuristic)	no

Also known as: bladder flat intraepithelial lesion · flat intraepithelial lesion of the bladder · flat intraepithelial lesion of the urinary bladder · urinary bladder flat intraepithelial lesion

Disease family

This is a subtype of urinary bladder neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › bladder flat intraepithelial lesion

Related subtypes (5): bladder benign neoplasm, urinary bladder cancer, urinary bladder villous adenoma, bladder papillary urothelial neoplasm, bladder inflammatory myofibroblastic tumor

Subtypes (1): bladder carcinoma in situ

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.